TITLE

ONCOGENEX BEGINS FIRST OF 4 PHASE 2 CLINICAL OGX-011 TRIALS

PUB. DATE
September 2005
SOURCE
Worldwide Biotech;Sep2005, Vol. 17 Issue 9, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that OncoGenex Technologies Inc. has initiated a phase two clinical trial of OGX-011 in newly diagnosed, previously untreated patients with clinically localized, high-risk prostate carcinoma. Objective of the clinical trial; Comments from Scott Cormack, president and CEO of OncoGenex; Preliminary results from three phase one clinical trials of OGX-011.
ACCESSION #
18070175

 

Related Articles

  • OncoGenex Reports Response Data from OCX-011 Phase II. Shrine, Jim // BioWorld Today;4/18/2007, Vol. 18 Issue 75, p3 

    The article reports on the results of the phase 2 trial of OGX-011 conducted by OncoGenex Technologies Inc. The clinical trial focused on using OGX-011 with docetaxel to treat metastatic breast cancer in patients. Results of the study revealed that nine of the fifteen patients involved had tumor...

  • OncoGenex Gets SPA for Phase III HRPC Trial.  // Bioworld Week;7/21/2008, Vol. 16 Issue 29, p3 

    The article reports that OncoGenex Technologies Inc. reached an agreement with the U.S. Food and Drug Administration under a special protocol assessment for a pivotal Phase III trial with lead compound OGX-011 in hormone refractory prostate cancer (HRPC). It states that the trial will enroll 765...

  • Will radical prostatectomy become obsolete?  // Contemporary Urology;Oct2002, Vol. 14 Issue 10, p75 

    Focuses on the use of prostate brachytherapy in the treatment of patients with clinically localized carcinoma. Increased awareness of clinical efficacy data associated with prostate brachytherapy; Overall biochemical progression-free survival rate for patients treated with brachytherapy as...

  • Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer. Chin, J. L.; Ng, C-K; Touma, N. J.; Pus, N. J.; Hardie, R.; Abdelhady, M.; Rodrigues, G.; Radwan, J.; Venkatesan, V.; Moussa, M.; Downey, D. B.; Bauman, G. // Prostate Cancer & Prostatic Diseases;2008, Vol. 11 Issue 1, p40 

    The objective was to evaluate the relative efficacy of cryoablation (CRYO) versus external beam radiation (EBRT) for clinically locally advanced prostate cancer in a randomized clinical trial. Patients with histologically proven, clinically staged as T2C, T3A or T3B disease were randomized with...

  • CLINIC ROUNDUP.  // BioWorld Today;7/17/2008, Vol. 19 Issue 138, p4 

    This section offers clinic roundup. According to AFFiRiS GmbH, it has completed recruiting all 24 Alzheimer's patients planned for its Phase I trial of AFF001. Compugen Ltd. has also begun the planning for a proof-of-concept human trial for CGEN-50001, a known central nervous system drug. In...

  • Measurement Equivalence and feasibility of the EORTC QLQ-PR25: paper-and-pencil versus touchscreen administration. Yu-Jun Chang; Chih-Hung Chang; Chiao-Ling Peng; Hsi-Chin Wu; Hsueh-Chun Lin; Jong-Yi Wang; Tsai-Chung Li; Yi-Chun Yeh; Wen-Miin Liang // Health & Quality of Life Outcomes;2014, Vol. 12 Issue 1, p1 

    Objective We assessed the measurement equivalence and feasibility of the paper-and-pencil and touchscreen modes of administration of the Taiwan Chinese version of the EORTC QLQ-PR25, a commonly used questionnaire to evaluate the health-related quality of life (HRQOL) in patients with prostate...

  • Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial. Kellokumpu-Lehtinen, P-L; Hjälm-Eriksson, M; Thellenberg-Karlsson, C; Åström, L; Franzen, L; Marttila, T; Seke, M; Taalikka, M; Ginman, C // Prostate Cancer & Prostatic Diseases;2012, Vol. 15 Issue 3, p303 

    Background:Radical radiotherapy (RT) combined with androgen deprivation therapy is currently the standard treatment for elderly patients with localized intermediate- or high-risk prostate cancer (PC). To increase the recurrence-free and overall survival, we conducted an adjuvant, randomized...

  • Preliminary Data Demonstrate that 40 mg Daily Dose of Cabozantinib Yields a High Rate of Bone Scan Response in mCRPC.  // Biomedical Market Newsletter;11/14/2011, Vol. 21, p354 

    The article offers information on the 2 ongoing clinical trials in exploring the lower starting doses of cabozantinib in cancer patients in the U.S. It notes that the preliminary data from a phase 1 investigator-sponsored trial (IST) has demonstrated that the 40 milligram (mg) dose was...

  • Dendreon: promising prospects for Provenge.  // PharmaWatch: Cancer;Apr2005, Vol. 4 Issue 4, p4 

    The article announces the positive result of the clinical trial conducted by Dendreon Corp. for its immunotherapy Provenge when used in combination with Avastatin in prostate cancer patients. In the trial, patients with hormone-dependent prostate cancer who had undergone surgical or radiation...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics